U.S., Dec. 7 -- ClinicalTrials.gov registry received information related to the study (NCT03758612) titled 'Placebo-Controlled, Randomized, SAD Study to Evaluate the Safety, Tolerability, and PK of TBI-223 in Healthy Adults' on Nov. 20.
Brief Summary: Partially-Blinded, Placebo-Controlled, Randomized, Single Ascending Dose (SAD) with a Food Effect Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults.
Study Type: Interventional
Condition: * Tuberculosis
* Tuberculosis, Pulmonary
Intervention: * Drug: TBI-223 50mg
TBI-223 50 mg supplied for oral administration.
* Drug: Placebo for TBI-223 50mg
Matching placebo for TBI-223 50mg supplied for oral administration.
* Drug: TBI-223 100, 300, 600, 1...